Discover investment opportunities in Stocks Less Than 10 Cents using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Stocks Less Than 10 Cents using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Stocks Less Than 10 Cents using our Smart AI Filter.
6 stocks found for "Stocks Less Than 10 Cents"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.64 | ±100.0% | -0.4 | 0.00% | |||
0.54 | ±100.0% | -0.4 | 0.00% | |||
1.56 | ±100.0% | 0.0 | 0.00% | |||
0.77 | ±100.0% | 39.7 | 0.00% | |||
0.51 | ±100.0% | -1.9 | 0.00% | |||
0.59 | ±100.0% | -0.1 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
On Friday, Virpax Pharmaceuticals, Inc. VRPX completed the full study following the initial Probudur pilot study performed by the U.S. Army Institute of Surgical Research (USAISR) under an existing Cooperative Research and Development Agreement (CRADA).
Read moreBrett Winton, ARK Invest Chief Futurist, expects a new platform to emerge as the world enters a "new operating system era", adding that it will likely accrue most of the gains when it comes to AI.
Read moreAfter surging 400% yesterday, Aethlon Medical, Inc. (NASDAQ: AEMD) shares are trading lower after the company announced a 1.38-million share registered direct offering priced at $9 per share. The gross proceeds to Aethlon, before deducting placement agent fees and other offering expenses, are expected to be approximately $12.425 million.
Read moreQ: What factors contribute to the low share price of NCNA?
A: NCNA's stock at under 10 cents may reflect market concerns about its liquidity, financial stability, or recent performance milestones. Investors should analyze recent earnings reports, cash flow statements, and industry trends to understand its valuation.
Q: How have the biotech stocks like SYRS and SPRB performed historically in bear markets?
A: Historically, biotech stocks such as SYRS and SPRB can be highly volatile in bear markets due to their dependence on clinical trial outcomes and funding. However, breakthroughs or positive trials might lead to quick stock recoveries.
Q: Why might some investors consider LDTC's stock despite its low price?
A: Investors may consider LDTC's stock if they perceive potential growth drivers, like innovative projects or partnerships. However, its low price suggests potential risks or market uncertainties that warrant further investigation.
Q: What risks might investors face with VINC in the current economic climate?
A: VINC, trading under 10 cents, may face risks such as limited capitalization, operational cash flow deficits, or sector-specific pressures. Economic downturns can amplify financial vulnerabilities, requiring thorough due diligence.
Q: Is BIOL’s current valuation typical for dental technology companies?
A: BIOL's low share price might not be typical for dental tech firms, suggesting it could be experiencing financial difficulties. Investors should review its competitive positioning and recent financial disclosures to gauge sector alignment.
Q: How do regulatory changes impact healthcare stocks like AWH and VIRX?
A: Healthcare stocks like AWH and VIRX can be significantly affected by regulatory shifts in drug approvals and healthcare policies. Changes can either accelerate growth opportunities or introduce new compliance costs.